Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574845 | 0.92 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3L3MBTL1HTR2A | |
| SCHEMBL6574966 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3L3MBTL1HTR6 | |
| SCHEMBL6573499 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL7806038 | 0.83 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HTR6ALDH1A1 | |
| SCHEMBL6573568 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL1335541 | 0.80 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL7215873 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR6ALDH1A1 | |
| SCHEMBL7809824 | 0.78 | SLC6A3 (0.60) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL1334034 | 0.77 | BCHE (0.44) | — | |
| SCHEMBL1021888 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3HTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149095-B1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH AS (DK) | 2004-01-21 | — | — | EP | disclosed |
| US-6617459-B2 | 8-azabicyclo(3.2.1)oct-2-ene and 9-azabicyclo(3.3.1)non-2-ene derivatives; monoamine neurotransmitter and serotonine reuptake inhibitors; radionuclide-labeled derivatives for diagnosis and detection | NEUROSEARCH A/S (DK) | 2003-09-09 | — | — | US | disclosed |
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | ANIONA APS (DK) | 2001-11-29 | — | — | US | disclosed |
| EP-1149095-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044746-A1 | NOVEL AZABICYCLO DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047028-A1 | Novel azabicyclo derivatives and their use | TACR2, TACR3, GPR68 | SLC6A2 551/4885SLC6A4 519/4885SLC6A3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.